Hypertension Management: Lifestyle, Medications, Devices & Surgical Options

Effective hypertension (HTN) management requires a personalized, stepped-care approach integrating lifestyle modification, pharmacotherapy, and — for resistant cases — device or surgical interventions. This guide aligns with ACC/AHA 2017, ESC 2023, and KDIGO guidelines.

1. Lifestyle Modification: Foundation for All Patients

DASH Diet: 8–10 servings fruits/vegetables, 2–3 low-fat dairy, whole grains, lean protein, nuts/legumes; Na⁺ <1.5 g/day. Effect: -11/-6 mmHg.

Sodium Reduction: <2.3 g/day (ideally 1.5 g). Effect: -5/-3 mmHg. Read labels; 70% Na⁺ from processed/restaurant food.

Potassium Supplementation (Dietary): 3.5–5 g/day (bananas, potatoes, spinach, beans). Effect: -4/-2 mmHg. Caution: CKD, K⁺-sparing meds.

Weight Loss: 1 kg ≈ -1 mmHg. Target BMI <25; waist <102 cm (M), <88 cm (F).

Physical Activity: 150 min moderate / 75 min vigorous + 2× resistance/week. Effect: -5/-3 mmHg.

Alcohol Moderation: ≤2 drinks/day (M), ≤1 (F). Effect: -4/-3 mmHg.

Smoking Cessation: Acute BP spike per cigarette; long-term vascular benefit.

Stress Reduction: TM, mindfulness, biofeedback — modest BP effect, high CV benefit.

2. Pharmacotherapy: Evidence-Based Selection

First-Line Classes (Compelling Indications in Parentheses)

Class Examples Key Indications Cautions
ACE Inhibitors Lisinopril, ramipril, perindopril Diabetes, CKD, HFrEF, post-MI, LVH, proteinuria Cough (10–20%), angioedema (0.1–0.7%), hyperK⁺, bilateral RAS, pregnancy
ARBs Losartan, valsartan, olmesartan, telmisartan ACEi intolerance, same indications HyperK⁺, bilateral RAS, pregnancy
Thiazide/Thiazide-Like Chlorthalidone (preferred), indapamide, HCTZ Volume HTN, elderly, Black patients, isolated systolic HTN HypoK⁺, hyponatremia, hyperuricemia, hyperglycemia, gout
DHP-CCBs Amlodipine, nifedipine XL, felodipine Elderly, isolated systolic HTN, Black patients, angina, Raynaud's Peripheral edema, gingival hyperplasia, constipation

Second-Line / Add-On

  • β-Blockers: HFrEF, post-MI, angina, AF rate control, migraine. Not 1st-line uncomplicated HTN (less stroke protection, metabolic adverse). Carvedilol, nebivolol (vasodilating) preferred.
  • Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone 25–50 mg (resistant HTN — PATHWAY-2), eplerenone (if gynecomastia). Monitor K⁺, Cr.
  • Non-DHP CCBs: Diltiazem, verapamil — rate control + BP; avoid HFrEF.
  • Central Agents: Clonidine, methyldopa (pregnancy), guanfacine — adherence issues, rebound HTN.
  • Direct Vasodilators: Hydralazine, minoxidil — refractory only; require β-blocker + diuretic to counter reflex tachycardia/fluid retention.

3. Treatment Algorithms

  • Stage 1 (130–139/80–89): Lifestyle 3–6 mo; if ASCVD risk ≥10% or CVD/CKD/DM → add med.
  • Stage 2 (≥140/90): Start 2 drugs (SPC preferred) — typically ACEi/ARB + CCB or thiazide.
  • Black Adults: Thiazide or CCB first; add ACEi/ARB for renal/CV protection.
  • Goal: <130/80 (most); <140/90 (frail elderly, standing hypotension).

4. Device Therapies (Resistant HTN: uncontrolled on 3 drugs incl. diuretic at max doses)

  • Renal Denervation (RDN): Radiofrequency (Symplicity Spyral) or ultrasound (Paradise) ablation of renal sympathetic nerves. SPYRAL HTN-OFF/ON MED, RADIANCE-HTN SOLO/TRIO: ~5–10 mmHg office BP reduction, sustained 3 yr. FDA approved 2023 (Symplicity). Candidate: eGFR >40, anatomy suitable, adherent to meds.
  • Baroreflex Activation Therapy (BAT): Carotid sinus stimulator (Barostim NEO). FDA for resistant HTN + HFrEF. Invasive.
  • Arteriovenous Anastomosis (ROX Coupler): Iliac AV fistula — reduces TPVR. Investigational.

5. Surgical / Secondary HTN Correction

  • Renovascular HTN: Fibromuscular dysplasia (PTA ± stent); atherosclerotic RAS (stent if flash pulmonary edema, refractory HTN, declining renal function — CORAL trial: no benefit for stable).
  • Primary Aldosteronism: Adrenalectomy (unilateral adenoma); MRA (bilateral hyperplasia).
  • Pheochromocytoma: α-blockade → β-blockade → adrenalectomy.
  • Cushing's: Transsphenoidal adenomectomy / adrenalectomy.
  • Coarctation of Aorta: Stent / surgical repair.

6. Monitoring & Adherence Optimization

  • Home BP Monitoring (HBPM): Validated device, proper technique, 7-day average (discard day 1). Target <130/80.
  • Ambulatory BP Monitoring (ABPM): Gold standard for diagnosis, white-coat/masked HTN, nocturnal dipping.
  • Adherence: SPC, pill boxes, pharmacy sync, digital reminders, motivational interviewing. Non-adherence = #1 cause of resistant HTN.
  • Labs q3–6 mo: BMP (K⁺, Cr, eGFR), lipids, glucose, uric acid.

Clinical Pearl: HTN control is a team sport. Pharmacist-led management, nurse titration protocols, community health worker support, and telemonitoring all improve control rates beyond physician-only care.

Hypertension - Related Articles